Claims for Patent: 5,811,562

Summary for Patent: 5,811,562

Title:	Vitamin-D amide derivatives
Abstract:	The present invention relates to compounds of general formula (I) ##STR1## where R.sup.1 and R.sup.2, which may be the same or different, each represent a hydrogen atom or an aliphatic, cycloaliphatic, araliphatic or aryl group or together with the nitrogen atom to which they are attached form a heterocyclic group; R.sup.3 represents a methyl group having .alpha.- or .beta.-configuration; one of R.sup.a and R.sup.b represents a hydroxy group or protected hydroxy group and the other represents a hydrogen atom; Y represents a valence bond or an alkylene group containing up to 3 carbon atoms; and A= represents a cyclohexylidene moiety characteristic of the A-ring of a 1.alpha.-hydroxylated vitamin D or analogue thereof. Active compounds of the invention exhibit separation of cell modulating and calcaemic activities coupled with enhanced duration of activity.
Inventor(s):	Hesse; Robert Henry (Winchester, MA), Setty; Sundara Katugam Srinivasasetty (Cambridge, MA)
Assignee:	Research Institute for Medicine and Chemistry Inc. (Cambridge, MA)
Application Number:	08/704,613
Patent Claims:	1. Compounds of general formula (I) ##STR13## where R.sup.1 and R.sup.2, which may be the same or different, each represent a hydrogen atom or an aliphatic, cycloaliphatic, araliphatic or aryl group or together with the nitrogen atom to which they are attached form a heterocyclic group; R.sup.3 represents a methyl group having .alpha.- or .beta.-configuration; one of R.sup.a and R.sup.b represents a hydroxy group or protected hydroxy group and the other represents a hydrogen atom; Y represents a valence bond or an alkylene group containing up to 3 carbon atoms; and A= represents a cyclohexylidene moiety characteristic of the A-ring of a 1.alpha.-hydroxylated vitamin D or analogue thereof. 2. Compounds as claimed in claim 1 in which R.sup.1 and R.sup.2 are each selected from hydrogen atoms, lower alkyl, lower cycloalkyl, C.sub.6-12 aryl C.sub.1-4 alkyl and optionally substituted C.sub.6-12 aryl groups. 3. Compounds as claimed in claim 2 in which R.sup.1 and R.sup.2 are each selected from methyl, ethyl, isopropyl and phenyl groups. 4. Compounds as claimed in claim 1 in which R.sup.1 R.sup.2 N-represents a heterocyclic group comprising one or more 5- and/or 6-membered rings and optionally containing one or more further heteroatoms selected from O, N and S. 5. Compounds as claimed in claim 4 in which R.sup.1 R.sup.2 N-represents piperidino or morpholino. 6. Compounds as claimed in claim 1 in which one of R.sup.a and R.sup.b represents a protected hydroxy group wherein the protecting group is a lower alkyl group optionally interrupted by one or more oxygen atoms. 7. Compounds as claimed in claim 1 in which A= represents one of the groups ##STR14## where R.sup.4 and R.sup.5 are each selected from hydrogen atoms and O-protecting groups. 8. Compounds as claimed in claim 7 in which R.sup.4 and R.sup.5 represent etherifying silyl groups. 9. Compounds as claimed in claim 7 in which R.sup.4 and R.sup.5 are selected from hydrogen atoms and metabolically labile etherifying or esterifying groups. 10. Compounds as claimed in claim 1 wherein A= represents one of the groups ##STR15## 11. 20,20-Dimethyl, 20-methylene and 20-spirocyclopropyl analogues of compounds as claimed in claim 1. 12. Pharmaceutical compositions comprising an active compound as claimed in claim 1 in admixture with one or more physiologically acceptable carriers or excipients. 13. A method of treatment of a human or animal subject to promote treatment of osteoporosis, wound healing, suppression of parathyroid hormone or neoplastic disease, infection, bone disease, autoimmune disease, host-graft reaction, transplant rejection, inflammatory disease, neoplasia, hyperplasia, myopathy, enteropathy, spondylitic heart disease, dermatological disease, rheumatoid arthritis, psoriatic arthritis, or secondary hyperparathyroidism, comprising administration to said subject of an effective amount of an active compound as claimed in claim 1.

Details for Patent 5,811,562

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Nps Pharmaceuticals, Inc.	NATPARA	parathyroid hormone	For Injection	125511	01/23/2015		2014-03-23